Implications of the 2026 Dyslipidemia Guideline for Primary Prevention Statin Therapy
This cross-sectional study explores the 2026 guideline on dyslipidemia management, examining the population health impact on US adults recommended primary prevention statin therapy due to atherosclerotic cardiovascular disease risk.
We haven't written up this one. JAMA has the full story — the link below goes straight to it.